Childhood Atopic Dermatitis: Recent Advances in Understanding and Management

The presentation discusses recent advances in understanding and managing childhood atopic dermatitis (AD). Key topics include the concept of preclinical atopic dermatitis, emphasizing the importance of early life skin barrier formation and the microbiome’s role. The breakdown of filaggrin, a crucial epidermal protein, is highlighted as a response mechanism to environmental changes post-birth, influencing skin barrier function. Early identification of filaggrin mutation carriers may predict severe AD development in infants. The presentation introduces the STAP AD trial, demonstrating that early intervention from birth can reduce AD incidence. The roles of various topical therapies, such as ruxolitinib and dupilumab, are explored, noting improvements in bone health and growth velocity in children with AD. The speaker emphasizes the potential for disease modification through well-designed interventions, acknowledging that while there are promising signals, rigorous studies are needed. Overall, focused strategies could enhance patient outcomes and address comorbidities associated with this condition.